Renaissance Capital logo

Kidney diagnostics developer Renalytix AI files for an $86 million US IPO

June 24, 2020
RNLX

Renalytix AI, which is commercializing AI-powered diagnostic tests for kidney disease, filed on Wednesday with the SEC to raise up to $86 million in an initial public offering in the US.

The pre-revenue company is currently listed in London on the AIM under the ticker RENX; it closed Wednesday with a market cap of £303 million ($377 million).

The Cardiff, United Kingdom-based company was founded in 2018 and plans to list on the Nasdaq under the symbol RNLX. Renalytix AI filed confidentially on May 15, 2020. J.P. Morgan and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.